Publications by authors named "M Yu Puchkova"
Article Synopsis
- - Prolgolimab is an improved anti-PD-1 antibody that shows strong efficacy in treating metastatic melanoma and features a modified LALA mutation.
- - Comparative studies indicate that prolgolimab has higher PD-1 receptor occupancy and T-cell activation than conventional antibodies like nivolumab and pembrolizumab, while showing less activation of antibody-dependent cellular phagocytosis.
- - In mouse studies, prolgolimab inhibited tumor growth by 56%, significantly outperforming pembrolizumab's 16% inhibition, suggesting a need for clinical comparisons between IgG1 and IgG4 anti-PD-1 antibodies.
PD-1/PD-L1-based therapy has been named a revolution in cancer treatment. By the end of 2018, more than 100 anti-PD-1 and anti-PD-L1 antibodies were in various stages of development, and more than 2000 clinical trials with their use have been registered. Characterization of such antibodies requires a bioassay to determine their biological activity.
View Article and Find Full Text PDF